AR093318A1 - Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) - Google Patents
Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc)Info
- Publication number
- AR093318A1 AR093318A1 ARP130103990A ARP130103990A AR093318A1 AR 093318 A1 AR093318 A1 AR 093318A1 AR P130103990 A ARP130103990 A AR P130103990A AR P130103990 A ARP130103990 A AR P130103990A AR 093318 A1 AR093318 A1 AR 093318A1
- Authority
- AR
- Argentina
- Prior art keywords
- hcc
- oxo
- treatment
- hepatocellular carcinoma
- piridazine
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 6
- -1 1-methyl-piperidin-4-ylmethoxy Chemical group 0.000 abstract 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007494 | 2012-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093318A1 true AR093318A1 (es) | 2015-05-27 |
Family
ID=47143496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103990A AR093318A1 (es) | 2012-11-02 | 2013-11-01 | Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150283137A1 (enExample) |
| EP (1) | EP2914264B1 (enExample) |
| JP (1) | JP6255028B2 (enExample) |
| KR (1) | KR102131588B1 (enExample) |
| CN (1) | CN104768553A (enExample) |
| AR (1) | AR093318A1 (enExample) |
| AU (1) | AU2013339823B2 (enExample) |
| BR (1) | BR112015008279A2 (enExample) |
| CA (1) | CA2890273C (enExample) |
| DK (1) | DK2914264T3 (enExample) |
| ES (1) | ES2646913T3 (enExample) |
| HK (1) | HK1211869A1 (enExample) |
| HR (1) | HRP20171295T1 (enExample) |
| HU (1) | HUE035483T2 (enExample) |
| IL (1) | IL238536B (enExample) |
| LT (1) | LT2914264T (enExample) |
| MX (1) | MX354518B (enExample) |
| NO (1) | NO2914264T3 (enExample) |
| PL (1) | PL2914264T3 (enExample) |
| PT (1) | PT2914264T (enExample) |
| RS (1) | RS56485B1 (enExample) |
| RU (1) | RU2650679C2 (enExample) |
| SG (1) | SG11201503214YA (enExample) |
| SI (1) | SI2914264T1 (enExample) |
| WO (1) | WO2014067610A1 (enExample) |
| ZA (1) | ZA201503924B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921310C (en) | 2013-08-14 | 2021-04-20 | Yugenkaisha Japan Tsusyo | Hydroponic cultivation system, and plant factory comprising hydroponic cultivation system and expanded polystyrene foam greenhouse |
| LT3996688T (lt) * | 2019-07-10 | 2023-12-27 | Merck Patent Gmbh | Farmacinis preparatas |
| JP2022551672A (ja) * | 2019-10-14 | 2022-12-12 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 乳癌治療法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| KR101829595B1 (ko) * | 2009-01-08 | 2018-02-14 | 메르크 파텐트 게엠베하 | 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법 |
-
2013
- 2013-10-04 RU RU2015120692A patent/RU2650679C2/ru active
- 2013-10-04 AU AU2013339823A patent/AU2013339823B2/en active Active
- 2013-10-04 CN CN201380057293.0A patent/CN104768553A/zh active Pending
- 2013-10-04 KR KR1020157014482A patent/KR102131588B1/ko active Active
- 2013-10-04 DK DK13776720.8T patent/DK2914264T3/en active
- 2013-10-04 ES ES13776720.8T patent/ES2646913T3/es active Active
- 2013-10-04 PT PT137767208T patent/PT2914264T/pt unknown
- 2013-10-04 SG SG11201503214YA patent/SG11201503214YA/en unknown
- 2013-10-04 BR BR112015008279A patent/BR112015008279A2/pt not_active Application Discontinuation
- 2013-10-04 EP EP13776720.8A patent/EP2914264B1/en active Active
- 2013-10-04 RS RS20171129A patent/RS56485B1/sr unknown
- 2013-10-04 NO NO13776720A patent/NO2914264T3/no unknown
- 2013-10-04 LT LTEP13776720.8T patent/LT2914264T/lt unknown
- 2013-10-04 JP JP2015541023A patent/JP6255028B2/ja active Active
- 2013-10-04 WO PCT/EP2013/002998 patent/WO2014067610A1/en not_active Ceased
- 2013-10-04 HU HUE13776720A patent/HUE035483T2/hu unknown
- 2013-10-04 US US14/440,181 patent/US20150283137A1/en not_active Abandoned
- 2013-10-04 PL PL13776720T patent/PL2914264T3/pl unknown
- 2013-10-04 CA CA2890273A patent/CA2890273C/en active Active
- 2013-10-04 MX MX2015005265A patent/MX354518B/es active IP Right Grant
- 2013-10-04 HR HRP20171295TT patent/HRP20171295T1/hr unknown
- 2013-10-04 HK HK16100004.6A patent/HK1211869A1/xx unknown
- 2013-10-04 SI SI201330832T patent/SI2914264T1/sl unknown
- 2013-11-01 AR ARP130103990A patent/AR093318A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238536A patent/IL238536B/en active IP Right Grant
- 2015-06-01 ZA ZA2015/03924A patent/ZA201503924B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2914264A1 (en) | 2015-09-09 |
| MX2015005265A (es) | 2015-07-17 |
| HRP20171295T1 (hr) | 2017-10-20 |
| HK1211869A1 (en) | 2016-06-03 |
| CA2890273C (en) | 2021-10-26 |
| PT2914264T (pt) | 2017-11-14 |
| HUE035483T2 (hu) | 2018-05-02 |
| CA2890273A1 (en) | 2014-05-08 |
| SG11201503214YA (en) | 2015-05-28 |
| DK2914264T3 (en) | 2017-09-11 |
| AU2013339823A1 (en) | 2015-06-18 |
| IL238536A0 (en) | 2015-06-30 |
| US20150283137A1 (en) | 2015-10-08 |
| WO2014067610A1 (en) | 2014-05-08 |
| JP2015536957A (ja) | 2015-12-24 |
| KR102131588B1 (ko) | 2020-07-08 |
| BR112015008279A2 (pt) | 2017-07-04 |
| RU2650679C2 (ru) | 2018-04-17 |
| CN104768553A (zh) | 2015-07-08 |
| AU2013339823B2 (en) | 2018-01-04 |
| EP2914264B1 (en) | 2017-08-09 |
| PL2914264T3 (pl) | 2017-12-29 |
| KR20150079942A (ko) | 2015-07-08 |
| SI2914264T1 (sl) | 2017-12-29 |
| ES2646913T3 (es) | 2017-12-18 |
| MX354518B (es) | 2018-03-08 |
| NO2914264T3 (enExample) | 2018-01-06 |
| JP6255028B2 (ja) | 2017-12-27 |
| IL238536B (en) | 2019-01-31 |
| RS56485B1 (sr) | 2018-01-31 |
| RU2015120692A (ru) | 2016-12-27 |
| LT2914264T (lt) | 2017-11-10 |
| ZA201503924B (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE046008T2 (hu) | I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére | |
| CR20130649A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| EA201390275A1 (ru) | Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанол | |
| DK2373640T3 (da) | Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf | |
| EP2883875A4 (en) | N2, N4-BIS (4- (PIPERAZINE-1-YL) PHENYL) PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY UNINTENTIONAL SALT AND COMPOSITION THEREOF AS ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF CANCER | |
| SI2632921T1 (sl) | Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| PH12017500719A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| IL268128A (en) | n1-(4-(5-(cyclopropylmethyl)-1-methyl-1-h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or Iraki inhibitors for cancer therapy | |
| PH12019500252A1 (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
| AR093318A1 (es) | Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) | |
| BR112015010121A2 (pt) | inibidores de quinase de tirosina de bruton | |
| MX2011007990A (es) | Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma. | |
| CL2017001478A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) | |
| AR101523A1 (es) | Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1 | |
| PH12016500948A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib | |
| AR092991A1 (es) | Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek) | |
| AR099035A1 (es) | Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de células renales (rcc) | |
| NZ716494A (en) | Processes and intermediates for the preparation of a pde10 inhibitor | |
| UY34194A (es) | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? | |
| UY32493A (es) | " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones" | |
| UA98919U (ru) | 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность | |
| IT201700035938A1 (it) | Bocca di erogazione per bancomat, atm o accettatori di banconote |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |